Skip to content

Topical Amitriptyline 1% Gel for the Treatment of Burning Mouth Syndrome

Topical Amitriptyline 1% Gel for the Treatment of Burning Mouth Syndrome

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07214181
Acronym
TOP-AMI → TOPi
Enrollment
30
Registered
2025-10-09
Start date
2024-01-02
Completion date
2025-05-30
Last updated
2025-10-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burning Mouth Syndrome, Stomatodynia

Keywords

pain , Amitriptyline ; treatment

Brief summary

Burning mouth syndrome (BMS) is a chronic oral pain condition that causes a persistent burning or stinging sensation in the mouth, often without visible changes in the tissues. It mostly affects women in midlife and older age and can greatly reduce quality of life. This study reviewed the medical records of patients with BMS who were treated with a topical 1% amitriptyline gel. The aim was to evaluate whether this gel could reduce pain and to record any side effects. Patients applied the gel inside the mouth for several weeks. Pain intensity was measured using a 0-10 scale before and after treatment. We also collected information about patients' overall impression of improvement and any reported adverse events. By analyzing these retrospective data, we hope to provide real-world evidence on the effectiveness and safety of topical amitriptyline gel as a potential treatment option for patients with burning mouth syndrome.

Detailed description

Burning mouth syndrome (BMS) is a chronic oral pain condition that causes a persistent burning or stinging sensation in the mouth, often without visible changes in the tissues. It mostly affects women in midlife and older age and can greatly reduce quality of life. This study reviewed the medical records of patients with BMS who were treated with a topical 1% amitriptyline gel. The aim was to evaluate whether this gel could reduce pain and to record any side effects. Patients applied the gel inside the mouth for several weeks. Pain intensity was measured using a 0-10 scale before and after treatment. We also collected information about patients' overall impression of improvement and any reported adverse events. By analyzing these retrospective data, we hope to provide real-world evidence on the effectiveness and safety of topical amitriptyline gel as a potential treatment option for patients with burning mouth syndrome.

Interventions

DRUGTopical amitriptyline 1% gel

Patients diagnosed with burning mouth syndrome received topical amitriptyline 1% gel applied intraorally. The gel was instructed to be placed on the oral mucosa (tongue and/or other symptomatic areas) two times per day for several weeks, without swallowing. Treatment was provided as part of routine clinical care. This retrospective study collected data on pain intensity, patient global impression of improvement, and adverse events to evaluate the real-world effectiveness and tolerability of this topical formulation.

Sponsors

Universidad de Murcia
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Adult patients diagnosed with burning mouth syndrome (BMS) according to international diagnostic criteria (ICHD-3 and ICOP). Symptoms recurring daily for \>50% of the day for at least 3 months. Pain intensity ≥4 on a 0-10 numerical rating scale (NRS) at baseline. Normal appearance of the oral mucosa and normal intraoral clinical examination. Received topical amitriptyline 1% gel as part of routine care.

Exclusion criteria

* Missing or incomplete medical records.Use of other concomitant topical treatments on the oral mucosa during the study period. * Change in systemic pain medication while using topical amitriptyline gel. * Presence of local conditions and sytemic that could cause burning mouth symptoms (e.g., candidiasis, lichen planus, allergies, ).

Design outcomes

Primary

MeasureTime frameDescription
Title: Change in mean pain intensity (NRS 0-10)Baseline to 4 weeks after treatment initiationDescription: Pain intensity measured using a numerical rating scale (0 = no pain, 10 = worst possible pain). Mean daily score calculated from patient records at baseline (before treatment) and after 4 weeks of topical amitriptyline gel.

Secondary

MeasureTime frameDescription
Patient Global Impression of Improvement (PGI-I)Time Frame: At 4 weeksDescription: Patient-reported overall improvement, categorized as very much better, much better, a little better, no change, or worse.

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026